Pirfenidone	NNP
for	IN
the	DT
treatment	NN
of	IN
idiopathic	JJ
pulmonary	JJ
fibrosis	NN
.	.

Idiopathic	JJ
pulmonary	JJ
fibrosis	NN
(	(
IPF	NN
)	)
is	VBZ
an	DT
under-recognised	JJ
,	,
rare	JJ
,	,
progressive	JJ
disease	NN
of	IN
the	DT
lungs	NNS
with	IN
unknown	JJ
aetiology	NN
and	CC
high	JJ
mortality	NN
.	.

The	DT
currently	RB
advocated	VBN
pathogenic	JJ
mechanism	NN
is	VBZ
represented	VBN
by	IN
progressive	JJ
multifocal	JJ
fibrosis	NN
.	.

It	PRP
is	VBZ
diagnosed	VBN
based	VBN
on	IN
clinical	JJ
,	,
radiographic	JJ
,	,
physiological	JJ
and	CC
histopathological	JJ
criteria	NNS
.	.

Existing	VBG
therapeutic	JJ
guidelines	NNS
recommend	VBP
anti-inflammatory	JJ
and	CC
immunosuppressive	JJ
combinations	NNS
,	,
despite	IN
proven	JJ
limited	JJ
efficacy	NN
.	.

There	EX
is	VBZ
no	DT
therapy	NN
approved	VBD
specifically	RB
for	IN
IPF	NN
,	,
but	CC
several	JJ
antifibrotic	JJ
agents	NNS
are	VBP
currently	RB
under	IN
development	NN
for	IN
this	DT
indication	NN
.	.

Pirfenidone	NNP
is	VBZ
an	DT
antifibrotic	JJ
agent	NN
potentially	RB
effective	JJ
for	IN
IPF	NN
therapy	NN
,	,
and	CC
preclinical	JJ
and	CC
available	JJ
clinical	JJ
data	NNS
support	VBP
its	PRP$
use	NN
in	IN
IPF	NN
.	.

Future	JJ
clinical	JJ
studies	NNS
are	VBP
expected	VBN
to	TO
provide	VB
more	JJR
consistent	JJ
information	NN
on	IN
survival	NN
benefit	NN
,	,
lung	NN
function	NN
and	CC
health-related	JJ
quality	NN
of	IN
life	NN
.	.

